Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2018

View Archived Issues

Alnylam Pharmaceuticals presents novel siRNAs for muscle atrophy

University of Pennsylvania divulges ZEBOV-targeting antibodies

Enterome patents antigenic peptides for cancer

Clinical study shows potential of ranolazine in paramyotonia congenita

REGN-4659 demonstrates antitumor activity in vivo

Janssen monoclonal antibody JNJ-64164711 depletes Tregs in tumor samples

ITI-214, a potential candidate for the treatment of Parkinson's disease

Biktarvy granted positive opinion in Europe

EMA's CHMP adopts positive opinion for Dzuveo

INSYS initiates phase II study of cannabidiol oral solution for treatment of Prader-Willi syndrome

Tagrisso receives positive opinion in Europe for first-line EGFR-mutated NSCLC

DisperSol initiates phase II trials of DST-0509 in iron overload disorder

Advantagene and BMS enter clinical trial collaboration

EMA committee recommends approval of Prolia for bone loss associated with glucocorticoid therapy

EMA committee hands down positive opinion for Cimzia in moderate to severe plaque psoriasis

FDA grants orphan drug designation to ELX-02 for cystinosis

Enrollment open in phase II study of dutogliptin for early recovery post-myocardial infarction

Bolder completes phase I study of long-acting G-CSF analogue BBT-015

FDA grants priority review to cemiplimab BLA for metastatic or advanced CSCC

Photoacoustic imaging agents for Alzheimer's disease described in KAERI patent

Chinese researchers patent deuterated derivatives of vonoprazan fumarate

AbbVie reviews milestones of first quarter 2018

WXFL-1024H251 demonstrates promising antitumor activity in breast and lung cancer models

ACHIEVE II study of ubrogepant in acute migraine meets coprimary endpoints

Accelerator Life Science Partners launches Proniras

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026